Cognition Therapeutics Expands Industry-Leading Expertise in Research and Clinical Use of Biomarkers of Alzheimer’s Disease November 27, 2018 Read More »
Cognition Therapeutics Initiates Patient Dosing in Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer’s Disease November 8, 2018 Read More »
Cognition Therapeutics to Sponsor Third International Symposium on Sigma-2 Receptors: Role in Health and Disease during the Society for Neuroscience Annual Meeting October 24, 2018 Read More »
Cognition Therapeutics Receives $16.6 Million Multiyear NIA Grant for Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer’s Disease October 2, 2018 Read More »
Cognition Therapeutics Presents Additional Elayta™ Clinical Results during Alzheimer’s Association International Conference (AAIC) Symposium Session July 23, 2018 Read More »
Cognition Therapeutics Initiates NIA-Funded SPARC Study of Elayta™ to Assess Changes in Synaptic Density and Cognitive Performance in Alzheimer’s Disease June 18, 2018 Read More »
Cognition Therapeutics Initiates NIA-Funded SNAP study of Elayta™ to Measure Toxic Oligomer Displacement and Clearance in Alzheimer’s Disease June 5, 2018 Read More »
Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum June 4, 2018 Read More »
Cognition Therapeutics Receives $6.6M in NIA Grants for Two Studies of Elayta™ to Expand Understanding of Synaptoprotective Mechanism of Action May 22, 2018 Read More »
Cognition Therapeutics Presenting Evidence for Elayta Synaptic Protection in Alzheimer’s Patients at Combined AAT-AD/PD Focus Meeting March 14, 2018 Read More »
Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at the Annual ASENT Meeting March 6, 2018 Read More »
Cognition Therapeutics to Participate in Leerink Partners 7th Annual Global Healthcare Conference February 12, 2018 Read More »
Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference November 8, 2017 Read More »
Cognition Therapeutics’ Alzheimer’s Disease Candidate CT1812 Meets Phase 1b/2a Study Objectives: Well Tolerated with Positive Influence on Biomarkers of Synapse Recovery November 4, 2017 Read More »
Cognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting on November 2nd and 4th October 30, 2017 Read More »
Cognition Therapeutics Announces Issuance of Broad Composition of Matter Patent for CT1812, a First-in-Class Alzheimer’s Disease Clinical Candidate October 24, 2017 Read More »
Cognition Therapeutics Receives Fast Track Designation from U.S. FDA for First-in-Class Alzheimer’s Candidate, CT1812 October 16, 2017 Read More »
Cognition Therapeutics CEO Kenneth I. Moch to Present at Ladenburg Thalmann 2017 Healthcare Conference September 20, 2017 Read More »
Cognition Therapeutics CEO Kenneth I. Moch Hosting One-on-Ones at Mizuho Securities CNS Deep Management Day September 7, 2017 Read More »
Function of Cognition Therapeutics’ Neurological Drug Screening Platform Presented at American Chemical Society National Meeting August 23, 2017 Read More »
Cognition Therapeutics Elects Lazard Vice Chairman Stephen Sands to Board of Directors August 2, 2017 Read More »
Cognition Therapeutics CEO Kenneth I. Moch to Present at Canaccord Genuity Annual Growth Conference July 31, 2017 Read More »
Cognition Therapeutics Reports Drug-Drug Interaction Results for CT1812, a Disease-Modifying Alzheimer’s Disease Candidate July 19, 2017 Read More »
Cognition Therapeutics CEO Kenneth I. Moch Presenting at BioCentury Future Leaders Conference April 3, 2017 Read More »
Cognition Therapeutics initiates US clinical testing of CT1812, a novel strong molecule for the potential treatment of Alzheimer’s disease December 13, 2016 Read More »
Cognition Therapeutics to Highlight CT1812 Safety Data at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting December 5, 2016 Read More »
Society for Neuroscience 2016 Nanosymposium Explores Potential of “Sigma-2/PGRMC1 Receptor Function in Disease and Therapeutics” November 30, 2016 Read More »
CogRx Sees Lilly Solanezumab Results as Support for its Unique Mechanism for Treatment of Alzheimer’s Disease November 23, 2016 Read More »
Cognition Therapeutics Announces Dosing of First Alzheimer’s Patient in Phase 1b Trial of CT1812 November 11, 2016 Read More »
Alzheimer’s Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO October 28, 2016 Read More »
Cognition Therapeutics (CogRx) Receives Michael J. Fox Foundation Grant to Study Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson’s Disease September 29, 2016 Read More »
Cognition Therapeutics Completes Oversubscribed $12 Million Series B Financing September 8, 2015 Read More »
NIH to Fund CogRx’s Strong Molecule Soluble Abeta Receptor Antagonist Program for Treatment of AD May 21, 2014 Read More »
Cognition Therapeutics, Inc. (CogRx) receives a US Patent for a Drug to Fight Alzheimer’s Disease April 1, 2014 Read More »
